Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
Public ClinicalTrials.gov record NCT04516967. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Double-blind, Placebo-controlled Study With Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Phase 3b Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for ≥6 Months
Study identification
- NCT ID
- NCT04516967
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 75 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 1 Year to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 5, 2021 (Actual)
- Primary completion
- Nov 8, 2023 (Actual)
- Completion
- Oct 28, 2025 (Actual)
- Last update posted
- Jun 3, 2026
2021 – 2025
United States locations
- U.S. sites
- 21
- U.S. states
- 17
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 112 | Phoenix | Arizona | 85016 | — |
| Site 103 | Long Beach | California | 90806 | — |
| Site 119 | Orange | California | 92868 | — |
| Site 109 | Sacramento | California | 95817 | — |
| Site 101 | San Francisco | California | 94158 | — |
| Site 111 | Aurora | Colorado | 80045 | — |
| Site 120 | Wilmington | Delaware | 19803 | — |
| Site 117 | Gainesville | Florida | 32610 | — |
| Site 116 | Atlanta | Georgia | 30322 | — |
| Site 107 | Peoria | Illinois | 61615 | — |
| Site 104 | Boston | Massachusetts | 02115 | — |
| Site 105 | Minneapolis | Minnesota | 55404 | — |
| Site 114 | Jackson | Mississippi | 39216 | — |
| Site 102 | Las Vegas | Nevada | 89135 | — |
| Site 108 | Morristown | New Jersey | 07960 | — |
| Site 118 | Charlotte | North Carolina | 28203 | — |
| Site 113 | Durham | North Carolina | 27710 | — |
| Site 106 | Columbus | Ohio | 43205 | — |
| Site 121 | Philadelphia | Pennsylvania | 19104 | — |
| Site 110 | Providence | Rhode Island | 02903 | — |
| Site 115 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04516967, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 3, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04516967 live on ClinicalTrials.gov.